By Andrew M. Seaman NEW YORK (Reuters Health) - The sons and daughters of people who live very long lives tend to get the symptoms of Alzheimer's disease later than others, but they're not immune from the memory-robbing disease, according to a new study. Based on comparisons of people in their 90s, their spouses, siblings, children and their children's spouses, researchers found that the offspring of people with exceptional longevity were about 40 percent less likely than peers to be cognitively impaired between ages 65 and 79.

By Toni Clarke Washington (Reuters) - Tanning beds and sunlamps will be required to carry stronger warning labels under new regulations proposed by the U.S. Food and Drug Administration, which is also recommending the machines not be used by people under the age of 18. The FDA said on Monday that it plans to reclassify sunbeds from low-risk to moderate-risk products, meaning they will need to be cleared by the agency before being allowed onto the market.

By Trevor Stokes NEW YORK (Reuters Health) - Creatine, a supplement favored by bodybuilders, modestly boosted muscle strength in patients with fibromyalgia, Brazilian researchers report. Apart from helping with muscle weakness, though, the treatment had little effect on other symptoms of the mysterious disorder, such as chronic pain, fatigue, memory loss, depression, anxiety and sleeplessness.

(Reuters) - A panel of advisers to the U.S. health regulator said that risks outweighed the benefits in Delcath Systems Inc's cancer therapy for a rare form of eye cancer that spreads to the liver. The panel of independent experts voted 16-0 against the drug/device combination. The drug-device combination product consists of a chemotherapy drug, melphalan hydrochloride, and a device known as the Delcath Hepatic Delivery System. The two are combined in a single package known as the Melblez Kit.